Journal of Chronic Disease Prevention and Care
Open Access
ISSN: 3065-7059
Research Article
View / Download PDF
Budesonide –Oral Galenic Formulations For Chron Disease
Authors: Luisetto M. Mashori GR. Cabianca L. Latyshev O.
Abstract
Aim of this work is to verify the farmaceutical form of oral Budesonide compounded used in Chron’s disease : capsules delay release or oral suspension.
\r\n\r\nIn particular way the kinds of excipients or bases-veicle used in the galenic pharmacy. The therapeutic need require a release of the API in delayed release . The Budesonide show low systemic impacts due by its hepatic methabolism vs a tocipal effect useful in this pathology. Some formulation provided by various pharmacy are reported as well as new technology like the 3D-PRINTING systems for colonic targeting tablets.
Citation:
Luisetto M. Mashori GR. Cabianca L. Latyshev O. Budesonide –Oral Galenic Formulations For Chron Disease. 2024; 1(1).
DOI:
10.33425/3065-7059-1005
Editor-in-Chief
Antonio M. Esquinas
Bioenginner Medical | Politecnica de Cartagena Murcia
View full editorial board →
Journal Metrics
Impact Factor
1*
Acceptance Rate
70%
Time to first decision
6-10 Days
Submission to acceptance
12-15 Days